Background/Aims: Mutations of the endosomal chloride/proton exchanger gene, CLCN5, cause Dent’s disease, an X-linked recessive proximal tubular disorder. The renal endocytic system was found to be affected in clcn5 knockout mice. However, the impaired endocytic machinery of Dent’s disease patients has not been thoroughly investigated. Methods: The CLCN5 gene was sequenced in a Japanese patient with Dent’s disease and his family. The loss-of-function phenotype of the missense CLCN5 mutation was investigated by gene expression in Xenopus oocytes and CHO cells. Immunohistochemical analysis was performed on kidney biopsy specimens for endocytic machinery proteins, megalin, cubilin, and disabled-2 (Dab2) in proximal tubules. Results: Genomic analysis revealed a novel G-to-A transition at the first nucleotide of the 333rd codon of CLCN5, causing a substitution of glycine with arginine. Inefficient expression of the mutant gene in Xenopus oocytes resulted in abolished chloride currents. Impaired N-glycosylation of the mutant protein was evident in the DNA-transfected CHO cells. Proximal tubular expression of megalin, cubilin, and Dab2 was markedly reduced and irregular staining in some portions was observed in the patient compared with controls. Conclusions: A novel G333R CLCN5 mutation caused defective expression of megalin, cubilin, and Dab2 in a patient with Dent’s disease.

Keywords:
Cubilin, Dab2, Dent’s disease, Endocytosis, Megalin, Proximal tubule cells
1.
Picollo A, Pusch M: Chloride/proton antiporter activity of mammalian CLC proteins ClC-4 and ClC-5. Nature 2005;436:420–423.
2.
Scheel O, Zdebik AA, Lourdel S, Jentsch TJ: Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. Nature 2005;436:424–427.
3.
Hoopes RR Jr, Shrimpton AE, Knohl SJ, Hueber P, Hoppe B, Matyus J, Simckes A, Tasic V, Toenshoff B, Suchy SF, Nussbaum RL, Scheinman SJ: Dent disease with mutations in OCRL1. Am J Hum Genet 2005;76:260–267.
4.
Wrong OM, Norden AG, Feest TG: Dent’s disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 1994;87:473–493.
5.
Lloyd SE, Gunther W, Pearce SH, Thomson A, Bianchi ML, Bosio M, Craig IW, Fisher SE, Scheinman SJ, Wrong O, Jentsch TJ, Thakker RV: Characterisation of renal chloride channel, CLCN5, mutations in hypercalciuric nephrolithiasis (kidney stones) disorders. Hum Mol Genet 1997;6:1233–1239.
6.
Ludwig M, Utsch B, Monnens LA: Recent advances in understanding the clinical and genetic heterogeneity of Dent’s disease. Nephrol Dial Transplant 2006;21:2708–2717.
7.
Fisher SE, van Bakel I, Lloyd SE, Pearce SH, Thakker RV, Craig IW: Cloning and characterization of CLCN5, the human kidney chloride channel gene implicated in Dent disease (an X-linked hereditary nephrolithiasis). Genomics 1995;29:598–606.
8.
Dutzler R, Campbell EB, Cadene M, Chait BT, MacKinnon R: X-ray structure of a ClC chloride channel at 3.0 A reveals the molecular basis of anion selectivity. Nature 2002;415:287–294.
9.
Wu F, Roche P, Christie PT, Loh NY, Reed AA, Esnouf RM, Thakker RV: Modeling study of human renal chloride channel (hCLC-5) mutations suggests a structural-functional relationship. Kidney Int 2003;63:1426–1432.
10.
Devuyst O, Christie PT, Courtoy PJ, Beauwens R, Thakker RV: Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent’s disease. Hum Mol Genet 1999;8:247–257.
11.
Saito A, Pietromonaco S, Loo AK, Farquhar MG: Complete cloning and sequencing of rat gp330/‘megalin,’ a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 1994;9:9725–9729.
12.
Christensen EI, Birn H: Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002;3:256–266.
13.
Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama JJ, Gejyo F: Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 2004;145:3935–3940.
14.
Oyama Y, Takeda T, Hama H, Tanuma A, Iino N, Sato L, Kaseda R, Ma M, Yamamoto T, Fujii H, Kazama JJ, Odani S, Terada Y, Mizuta K, Gejyo F, Saito A: Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules. Lab Invest 2005;85:522–531.
15.
Oleinikov AV, Zhao J, Makker SP: Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. Biochem J 2000;347:613–621.
16.
Morris SM, Tallquist MD, Rock CO, Cooper JA: Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J 2002;21:1555–1564.
17.
Hocevar BA, Smine A, Xu XX, Howe PH: The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001;20:2789–2801.
18.
Piwon N, Gunther W, Schwake M, Bosl MR, Jentsch TJ: ClC-5 Cl–-channel disruption impairs endocytosis in a mouse model for Dent’s disease. Nature 2000;408:369–373.
19.
Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Lereth M, Guggino WB, Courtoy PJ: Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 2003;100:8472–8477.
20.
Santo Y, Hirai H, Shima M, Yamagata M, Michigami T, Nakajima S, Ozono K: Examination of megalin in renal tubular epithelium from patients with Dent disease. Pediatr Nephrol 2004;19:612–615.
21.
Yanagida H, Ikeoka M, Kuwajima H, Wada N, Tabata N, Sugimoto K, Okada M, Takemura T: A boy with Japanese Dent’s disease exhibiting abnormal calcium metabolism and osseous disorder of the spine: defective megalin expression at the brushborder of renal proximal tubules. Clin Nephrol 2004;62:306–312.
22.
Schmieder S, Lindenthal S, Banderali U, Ehrenfeld J: Characterization of the putative chloride channel xClC-5 expressed in Xenopus laevis oocytes and comparison with endogenous chloride currents. J Physiol 1998;511:379–393.
23.
Takeda T, Go WY, Orlando RA, Farquhar MG: Expression of podocalyxin inhibits cell-cell Adhesion and modifies junctional properties in Madin-Darby canine kidney cells, Mol Biol Cell 2000;11:3219–3232.
24.
Schmieder S, Bogliolo S, Ehrenfeld J: N-glycosylation of the Xenopus laevis ClC-5 protein plays a role in cell surface expression, affecting transport activity at the plasma membrane. J Cell Physiol 2007;210:479–488.
25.
Saito A, Yamazaki H, Rader K, Nakatani A, Ullrich R, Kerjaschki D, Orlando RA, Farquhar MG: Mapping rat megalin: the second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis. Proc Natl Acad Sci USA 1996;93:8601–8605.
26.
Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, Mishima Y, Hitomi J, Yamamoto T, Utsuyama M, Niwa O, Aizawa S, Kominami R: Bcl11b is required for differentiation and survival of αβ T lymphocytes. Nat Immunol 2003;4:533–539.
27.
Norden AG, Lapsley M, Igarashi T, Kelleher CL, Lee PJ, Matsuyama T, Scheinmen SJ, SHiraga H, Sundin DP, Thakker RV, Unwin RJ, Verroust P, Moestrup SK: Urinary megalin deficiency implicates abnormal tubular endocytic function in Fanconi syndrome. J Am Soc Nephrol 2002;13:125–133.
28.
Fyfe JC, Madsen M, Hojrup P, Christensen EL, Tanner SM, de la Chapelle A, He Q, Moestrup SK: The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood 2004;103:1573–1579.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.